Comparative Pharmacology
Head-to-head clinical analysis: SARISOL NO 1 versus SARISOL NO 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SARISOL NO 1 versus SARISOL NO 2.
SARISOL NO. 1 vs SARISOL NO. 2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination analgesic and muscle relaxant; orphenadrine is a centrally acting muscle relaxant that may exert its effects via inhibition of the reticular activating system and blockade of muscarinic receptors; aspirin inhibits cyclooxygenase enzymes, reducing prostaglandin synthesis and providing analgesic and anti-inflammatory effects; caffeine is a CNS stimulant that may enhance analgesia.
SARISOL NO. 2 contains butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation. Acetaminophen inhibits cyclooxygenase (COX) enzymes centrally, reducing pain and fever. Caffeine is a CNS stimulant that antagonizes adenosine receptors.
Butalbital 50 mg, acetaminophen 300 mg, and caffeine 40 mg orally every 4 hours as needed; maximum 6 tablets per day.
Butalbital 50 mg, acetaminophen 325 mg, and caffeine 40 mg per tablet; 1 to 2 tablets orally every 4 hours as needed, not to exceed 6 tablets per day.
None Documented
None Documented
Terminal elimination half-life is 10-12 hours in adults with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 12-15 hours; prolonged in hepatic impairment.
Renal (70-80% as unchanged drug, 10-15% as glucuronide conjugate); biliary/fecal (5-10%)
Renal excretion of unchanged drug and metabolites; 70% renal, 30% biliary/fecal.
Category C
Category C
Topical Anti-acne Agent
Topical Anti-acne Agent